^
    14d
    KN046-209: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=95, Completed, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting --> Completed | N=54 --> 95 | Trial completion date: Dec 2027 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation • EGFR negative
    |
    axitinib • erfonrilimab (KN046)
    24d
    Next-generation sequencing elucidates the distinct mutational landscape of SMARCA4-deficient lung cancer. (PubMed, Oncol Lett)
    The mutated genes were more resistant to the EGFR tyrosine kinase inhibitor. In conclusion, patients with SMARCA4-deficient lung cancer have distinct immunohistochemical characteristics, and SMARCA4 has been implicated in the incidence and progression of tumors through different mutation mechanisms.
    Journal • Next-generation sequencing • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PD-1 (Programmed cell death 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • TYMS (Thymidylate Synthetase) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • DPYD (Dihydropyrimidine Dehydrogenase) • XRCC1 (X-Ray Repair Cross Complementing 1) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    TP53 mutation • EGFR mutation • EGFR expression • EGFR negative
    25d
    Histology-Based Induction Chemoradiotherapy Followed by Surgery for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Prospective Observational Study. (PubMed, Ann Thorac Cardiovasc Surg)
    Histology-based induction CRT followed by surgery demonstrated feasibility and favorable outcomes, particularly for Sq and EGFR-negative non-Sq NSCLC. These findings provide a reference for patients ineligible for immune checkpoint inhibitor-based therapy.
    Observational data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR negative
    |
    cisplatin • pemetrexed • vinorelbine tartrate
    28d
    ACHIEVE Study: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
    P3, N=304, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2035 | Trial primary completion date: Jun 2026 --> Jan 2035
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    1m
    PRIMROSE: A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=334, Recruiting, AstraZeneca | N=234 --> 334 | Trial completion date: Feb 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    EGFR negative
    |
    Datroway (datopotamab deruxtecan-dlnk)
    1m
    Impact of EGFR Mutations on Survival and Clinical Response in Non-Small Cell Lung Cancer in a Tertiary Care Hospital. (PubMed, Clin Transl Sci)
    EGFR mutation status, brain metastases, and clinical response are key predictors of survival in NSCLC patients. Integrating genetic screening, timely management of brain metastases, and early assessment may enhance personalized treatment and improve prognosis.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive • EGFR negative
    1m
    BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=420, Recruiting, BioNTech SE
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • PD-L1 negative • RET mutation • MET mutation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
    1m
    A Phase II Study of GC101 in NSCLC (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Shanghai Juncell Therapeutics
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • MET exon 14 mutation • RET mutation • MET mutation • KRAS G12 • EGFR negative • NTRK fusion
    |
    GC101 TIL
    2ms
    Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial. (PubMed, Nat Commun)
    In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER + /HER2-) breast cancer > 20 mm and/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B). The predictive signature was independently validated in the CORALLEEN trial (pinteraction=0.048). Clinicaltrials.gov identifier: NCT02603679.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR negative
    |
    Ibrance (palbociclib) • paclitaxel
    2ms
    Glioblastoma Cells Expressing Oncogenic EGFR Release Multiple Extracellular Vesicle Subpopulations Positive or Negative for EGFR. (PubMed, J Extracell Biol)
    Overall, our results suggest that multiple pathways of EV biogenesis may operate in glioma cells resulting in formation of complex EV landscapes consisting of EGFR-positive and EGFR-negative EV subsets. This heterogeneity may have important implications for EV functions and EV-based diagnostics.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CD81 (CD81 Molecule)
    |
    EGFR expression • EGFR positive • EGFR negative
    3ms
    Clinical response and prognosis of estrogen receptor-positive and human epidermal growth factor receptor-negative breast cancer patients after neoadjuvant chemotherapy: a retrospective cohort study. (PubMed, Ann Surg Treat Res)
    In ER-positive, HER2-negative breast cancer, clinical responses and post-NAC Ki-67 were significant prognostic factors in patients aged ≤50 years but not in older patients. These findings highlight the need for tailored therapeutic approaches that consider age-specific prognostic differences.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR positive • EGFR negative • HER-2 negative + ER positive
    3ms
    SHARP: A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=15, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative